INTRODUCTION: The aim of this study was to investigate whe- ther X-ray repair cross-complementing group 3 (XRCC3) and xeroderma pigmentosum group D (XPD) single nucleotide polymorphism (SNP) affects the outcome of platinum- based chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients. MATERIAL AND METHODS: From September 2005 to June 2009, 355 advanced-stage NSCLC patients were accrued to compare the SNP variants with the outcome of platinum-based chemotherapy. TaqMan RT-PCR was used to evaluate the SNPs of the XRCC3 codon241 (Thr/Met) and XPD codon751 (Lys/Gln) DNA repair genes. RESULTS: There was a lack of association between the studied SNPs and the response rate, progression-free survival or overall survival (OS) in the whole population. However, subgroup analysis revealed that XRCC3 241 Thr/Met or Met/Met allele was associated with marginally significantly longer OS than XRCC3 Thr/Thr allele (19.0 m vs. 12.5 m, p=0.081) in the patients treated with gemcitabine/ cisplatin or carboplatin (GP/GC) while it was correlated with a significantly shorter OS in the patients treated with non GP/GC (9.3 m vs. 16 m, p=0.003). XPD751 Lys/Lys had an association with statistical significantly longer OS than XPD751 Lys/Gln or Gln/Gln in the subgroup of elderly patients (14.10 m vs. 10 m, p=0.019) and patients with non-adenocarcinoma (12.6 m vs. 9 m, p=0.042). CONCLUSIONS: XRCC3 Thr241Met played an opposite role in predicting prognosis of chemotherapy in NSCLC patients according to the first-line regimens. XPD 751 Lys/ Lys might be a better prognostic marker of elderly or noncarcinoma NSCLC subgroup treated with platinum-based chemotherapy.
INTRODUCTION: The aim of this study was to investigate whe- ther X-ray repair cross-complementing group 3 (XRCC3) and xeroderma pigmentosum group D (XPD) single nucleotide polymorphism (SNP) affects the outcome of platinum- based chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients. MATERIAL AND METHODS: From September 2005 to June 2009, 355 advanced-stage NSCLCpatients were accrued to compare the SNP variants with the outcome of platinum-based chemotherapy. TaqMan RT-PCR was used to evaluate the SNPs of the XRCC3 codon241 (Thr/Met) and XPD codon751 (Lys/Gln) DNA repair genes. RESULTS: There was a lack of association between the studied SNPs and the response rate, progression-free survival or overall survival (OS) in the whole population. However, subgroup analysis revealed that XRCC3 241 Thr/Met or Met/Met allele was associated with marginally significantly longer OS than XRCC3Thr/Thr allele (19.0 m vs. 12.5 m, p=0.081) in the patients treated with gemcitabine/ cisplatin or carboplatin (GP/GC) while it was correlated with a significantly shorter OS in the patients treated with non GP/GC (9.3 m vs. 16 m, p=0.003). XPD751 Lys/Lys had an association with statistical significantly longer OS than XPD751 Lys/Gln or Gln/Gln in the subgroup of elderly patients (14.10 m vs. 10 m, p=0.019) and patients with non-adenocarcinoma (12.6 m vs. 9 m, p=0.042). CONCLUSIONS:XRCC3 Thr241Met played an opposite role in predicting prognosis of chemotherapy in NSCLCpatients according to the first-line regimens. XPD 751 Lys/ Lys might be a better prognostic marker of elderly or noncarcinoma NSCLC subgroup treated with platinum-based chemotherapy.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: G Matullo; S Guarrera; S Carturan; M Peluso; C Malaveille; L Davico; A Piazza; P Vineis Journal: Int J Cancer Date: 2001-05-15 Impact factor: 7.396
Authors: R de las Peñas; M Sanchez-Ronco; V Alberola; M Taron; C Camps; R Garcia-Carbonero; B Massuti; C Queralt; M Botia; R Garcia-Gomez; D Isla; M Cobo; M Santarpia; F Cecere; P Mendez; J J Sanchez; R Rosell Journal: Ann Oncol Date: 2006-01-11 Impact factor: 32.976
Authors: D Isla; C Sarries; R Rosell; G Alonso; M Domine; M Taron; G Lopez-Vivanco; C Camps; M Botia; L Nuñez; M Sanchez-Ronco; J J Sanchez; M Lopez-Brea; I Barneto; A Paredes; B Medina; A Artal; P Lianes Journal: Ann Oncol Date: 2004-08 Impact factor: 32.976
Authors: Wei Zhou; Sarada Gurubhagavatula; Geoffrey Liu; Sohee Park; Donna S Neuberg; John C Wain; Thomas J Lynch; Li Su; David C Christiani Journal: Clin Cancer Res Date: 2004-08-01 Impact factor: 12.531
Authors: M Tarabichi; A Antoniou; M Saiselet; J M Pita; G Andry; J E Dumont; V Detours; C Maenhaut Journal: Cancer Metastasis Rev Date: 2013-12 Impact factor: 9.264